Number of Panel Genes20

Connective Tissue Gene Tests offers five panel options for osteogenesis imperfecta (OI) testing utilizing NextGen sequencing technology, an OI COL1A1 & COL1A2 panel, an OI core panel, a dominant OI panel, a recessive OI panel and a combined dominant and recessive OI panel.  In addition to genes associated with the autosomal dominant and autosomal recessive forms of OI, the panels also contain genes for disorders included in the differential diagnosis of OI.
 

Connective Tissue Gene Tests offers five panel options for osteogenesis imperfecta (OI) testing utilizing NextGen sequencing technology, an OI COL1A1 & COL1A2 panel, an OI core panel, a dominant OI panel, a recessive OI panel and a combined dominant and recessive OI panel.  In addition to genes associated with the autosomal dominant and autosomal recessive forms of OI, the panels also contain genes for disorders included in the differential diagnosis of OI.
 
The Recessive osteogenesis imperfecta panel consist of twenty genes: ALPL, BMP1, CREB3L1, CRTAP, FKBP10, LRP5, MBTPS2, P3H1, PLOD2, PLS3, PPIB, SEC24D, SERPINF1, SERPINH1, SP7, SPARC, TAPT1, TMEM38B, WNT1 and XYLT2.

Copy number variation (CNV) analysis of the Recessive osteogenesis imperfecta genes is also offered as a panel. Additionally, CTGT offers a comprehensive test (both NGS and CNV panels) for these genes. Panel genes are also offered as individual sequencing and deletion/duplication tests unless otherwise indicated.

OI Recessive Panel
Gene Disorder (MIM) MIM Inheritance
SERPINF1 Osteogenesis imperfecta, type VI (OI6) 613982 AR
CRTAP Osteogenesis imperfecta, type VII (OI7) 610682 AR
P3H1 (LEPRE1) Osteogenesis imperfecta, type VIII (OI8) 610915 AR
PPIB Osteogenesis imperfecta, type IX (OI9) 259440 AR
SERPINH1 Osteogenesis imperfecta, type X (OI10) 613848 AR
FKBP10 Osteogenesis imperfecta, type XI (OI11)
Bruck syndrome 1 (BRKS1)
610968
259450
AR
SP7 Osteogenesis imperfecta, type XII (OI12) 613849 AR
BMP1 Osteogenesis imperfecta, type XIII (OI13) 614856 AR
TMEM38B Osteogenesis imperfecta, type XIV (OI14) 615066 AR
WNT1 Osteogenesis imperfecta, type XV (OI15) 615220 AR
CREB3L1 Osteogenesis imperfecta, type XVI (OI16) 616229 AR
SPARC Osteogenesis imperfecta, type XVII (OI17) 616507 AR
ALPL Hypophosphatasia, adult
Hypophosphatasia, childhood
Hypophosphatasia, infantile
146300
241510
241500
AR/AD
LRP5 Osteoporosis-pseudoglioma syndrome (OPPG) 259770 AR
MBTPS2 Osteogenesis imperfecta, MBTPS2 related - XLR
PLOD2 Bruck syndrome 2 (BRKS2) 609220 AR
PLS3 PLS3 related Bone mineral density quantitative trait locus 18 (BMND18) 300910 XL
SEC24D Cole-Carpenter syndrome 2 (CLCRP2) 616294 AR
TAPT1 Osteochondrodysplasia, complex lethal, Symoens-Barnes-Gistelinck type (OCLSBG) 616897 AR
XYLT2 Spondyloocular syndrome (SOS) 605822 AR

 

 

Gene(s)

ALPL BMP1 CREB3L1 CRTAP FKBP10 LRP5 MBTPS2 P3H1 PLOD2 PLS3 PPIB SEC24D SERPINF1 SERPINH1 SP7 SPARC TAPT1 TMEM38B WNT1 XYLT2

Disease Group

Skeletal disorders

MIM

613982 610682 610915 259440 613848 610968 613849 614856 615066 615220 609220 146300 241500 241510 616229 616507 616294 616897

Methodology

Billing

CPT Code(s)
81479 x 1

Ordering

Test Code
5105

Additional Test Codes
5103 —Next Generation Sequencing Only, 5104 — Deletion / Duplication Only

Turnaround Time
Typically 2 to 4 weeks from receipt of a sample in the laboratory. All cases involving ongoing pregnancies will be expedited.

Prenatal Specimens
Cultured cells: 2 confluent T-25 flasks derived from amnio or CVS samples
Genomic DNA: minimum of 3 µg (at a concentration of at least 30 ng/µl)

Non-Prenatal Specimens
Whole blood: purple-top (EDTA) tube, minimum of 3 ml
Genomic DNA: a minimum of 3 µg (at a concentration of at least 30 ng/µl)
Fibroblasts: 2 confluent T-25 flasks
Saliva: only samples collected in Oragene DNA Self-Collection Kit or Oragene Saliva Collection Kit for Young Children are accepted

Shipping
Ship all specimen types at room temperature by overnight courier. Do not freeze.

The American Medical Association (AMA) Current Procedural Terminology (CPT) codes published by HNL Lab Medicine are guidelines and are intended for informational purposes only. CPT coding is the exclusive responsibility of the billing entity. HNL Lab Medicine strongly recommends confirmation of CPT codes with third-party payors and/or the AMA. We assume no responsibility for billing errors due to reliance upon CPT codes provided by HNL Lab Medicine.

News

October 28, 2022

Non-Hodgkin Lymphoma FISH Panel Now Available

B-cell lymphoma is a large group of heterogenous disorders and comprises a majority of non-Hodgkin lymphomas.
Read More
October 20, 2022

Genetic testing for Familial Transthyretin Amyloidosis (TTR) NOW AVAILABLE In-House

Hereditary amyloidosis is a life-threatening disorder that can lead to peripheral neuropathy and heart failure.
Read More
August 08, 2022

Familial hypercholesterolemia (FH)

Familial hypercholesterolemia (FH) is a genetic disorder that increases the likelihood of having coronary heart disease at a younger age. Learn about how to determine if you have hypercholesterolemia and what actions you can take to create better outcomes!

Read More
April 11, 2022

Genome Sequencing: A Vital Tool Used in Identifying and Tracking New COVID-19 Variants

Genome sequencing is reading or decoding the complete genetic information i.e. “Genome” of an organism that is encrypted in the form of a very long string called DNA made up of 4 letters, A, T, G, and C. The genome of an organism essentially determines their physical characteristics and ...
Read More
March 03, 2022

The Effect of Genetics on Individual Heart Health: Early Identification of FH Variations to Optimize Treatment

Test must be ordered by a Physician.

Familial hypercholesterolemia (FH) is a genetic disorder that is characterized by abnormally high blood levels of low-density lipoprotein (LDL) cholesterol, sometimes referred to as "bad cholesterol". This condition affects an estimated 1 in 250 people, and increases the likelihood of developing cardiovascular disease. In fact, FH is estimated to be the cause of 2-3% of heart attacks in individuals younger than age 60.

Read More